Rational design of small molecule RHOA inhibitors for gastric cancer

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Gastric cancer (GC) is a leading cause of cancer mortality worldwide.
• Ras homologous A (RHOA) is a key signaling hub implicated in GC progression.
• Targeting oncogenic signaling pathways is a critical strategy in cancer therapy.

Purpose of the Study:

• To pharmacologically optimize anti-RHOA hydrazide derivatives for enhanced anti-gastric cancer potency.
• To evaluate the efficacy of novel compounds JK-136 and JK-139 against gastric cancer.
• To investigate the molecular mechanisms underlying the action of these inhibitors.

Main Methods:

• Computational analysis and medicinal chemistry for drug optimization.
• In vitro assays assessing cell viability, migration, and invasion of GC cell lines.
• In vivo studies using mouse xenograft models.
• Network analysis to identify affected signaling pathways.

Main Results:

• Two optimized hydrazide derivatives, JK-136 and JK-139, demonstrated potent inhibition of GC cell viability and metastasis.
• JK-136 exhibited significantly higher binding affinity for RHOA compared to the nonclinical inhibitor Rhosin.
• Network analysis revealed downregulation of the sphingosine-1-phosphate pathway, impacting cell motility.

Conclusions:

• Targeting oncogenic signaling hubs like RHOA is a promising strategy for developing novel anti-cancer therapeutics.
• JK-136 and JK-139 represent potential new antineoplastic agents for gastric cancer and potentially other cancers.
• Further characterization and translation of these RHOA inhibitors are warranted.